Neurogene Inc. Share Price Börse Stuttgart
Equities
6AP
US64135M1053
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.05 EUR | -.--% | -2.42% | -46.46% |
06-03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
06-03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 492M 455M 38.65B |
---|---|---|---|---|---|
Net income 2024 * | -66M -61.11M -5.19B | Net income 2025 * | -78M -72.22M -6.13B | EV / Sales 2024 * | - |
Net cash position 2024 * | 327M 303M 25.71B | Net cash position 2025 * | 501M 464M 39.39B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.53
x | P/E ratio 2025 * |
-10.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.22% |
Latest transcript on Neurogene Inc.
1 week | -2.42% | ||
1 month | -8.33% | ||
3 months | -19.87% | ||
6 months | -38.27% | ||
Current year | -46.46% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- NGNE Stock
- 6AP Stock